Terns Pharmaceuticals (TERN – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...

William Blair initiated coverage of Terns Pharmaceuticals (TERN) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule ...

Terns Pharmaceuticals ( ($TERN) ) has issued an announcement. On February 22, 2025, Terns Pharmaceuticals announced the appointment of Andrew ...

Seasoned public company CFO with 25 years of leadership experience in biotechFOSTER CITY, Calif., Feb. 24, 2025 (GLOBE ...

Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, ...